Key Takeaways:
- EPS of -$0.11 beat consensus estimate of -$0.1377
- Revenue reached $190,000 versus expectations of zero
- The proteomics company reported Q2 2026 results on July 28
Back
Nautilus Biotechnology beats Q2 estimates with narrower $0.11 loss
Nautilus Biotechnology reported a Q2 loss of $0.11 per share, beating the $0.1377 consensus estimate by $0.0277.
Revenue reached $190,000, compared with analyst expectations of zero for the pre-commercial proteomics company. The company did not disclose guidance for the current quarter. Prior-year quarter figures were not yet available.
The narrower-than-expected loss and initial revenue represent a beat on both top and bottom lines. Nautilus, which develops the Proteograph platform for protein analysis, is in early stages of commercial adoption.
The Q2 beat points to potential momentum in the company's commercial strategy. Investors will watch for customer adoption metrics and platform deployment updates in coming quarters.
This article is for informational purposes only and does not constitute investment advice.
